Additional important safety considerations include: Risk of hypoglycaemia when combined with insulin or sulfonylureas Potential for dehydration and acute kidney injury from severe gastrointestinal symptoms Increased risk of diabetic retinopathy complications with rapid glucose lowering, particularly with semaglutide Importantly, memory loss or cognitive impairment is not listed among the recognised adverse effects in the Summary of Product Characteristics (SmPC) for any GLP-1 receptor agonist licensed in the UK
Edens GLP-1 treatment program connects individuals to licensed healthcare providers who can guide your treatment and tailor a plan to support your goals.Please note that you must complete a health assessment and eligibility is not guaranteed
The medication has a half-life of about seven days , which means that a missed dose can disrupt your progress, particularly if youre in the early stages of treatment
Check current peptide regulation updates for the latest information
Where and How to Inject Wegovy: A Complete Step-by-Step Guide Wegovy should be injected once weekly into the abdomen, thigh or upper arm, avoiding the navel area and rotating sites each week for comfort, safety
